Hepatitis C virus and non-Hodgkin’s lymphomas: Meta-analysis of epidemiology data and therapy options

Table 1 Main studies of antiviral therapy in patients with hepatitis C virus infection and non-Hodgkin’s lymphoma (reports with single cases were discarded)

Ref.	n	Lymphoma histology (n)	Disease sites BM-S-LN-PB	MC type II (n)	Antiviral therapy (n)	SVR (n)	NHL response (n)	Response duration (mo)
Mazzaro et al[94]	6	LPL (6)	6-0-2-0	4	IFN (6)	4	CR (3) PR (1)	12 (8-18)
Moccia et al[95]	3	SMZL (3)	1-3-0-0	NR	IFN (3)	2	CR (2) NR (1)	24 (5-40)
Hermine et al[80]	9	SLVL (9)	6-9-5-9	6	IFN (7) IFN-RBV (2)	7	CR (7) PR (1)	27 (15-40)
							NR (1)
Arcaini et al[96]	4	SMZL (4)	4-4-1-2	NR	IFN + RBV (4)	3	CR (2) PR (1)	36 (1-16)
Kelaidi et al[82]	8	SMZL (4) MZL/MALT (4)	7-6-2-6	8	IFN (2) IFN + RBV (6)	5	CR (5) PR (1)	6
Pitini et al[97]	2	SMZL (2)	2-2-1-2	NR	IFN (2)	2	CR (2)	9
Saadoun et al[83]	18	SLVL (18)	10-18-8-10	18	IFN (8) IFN + RBV (10)	14	CR (14) PR (4)	62
Tursi et al[89]	16	MZL/MALT (16)	NR	NR	IFN + RBV (16)	11	CR (11)	NotR
Vallisa et al[86]	13	SMZL (4) MALT (4) FL (1) LPL (4)	5-4-0-6	5	PEG-IFN + RBV (13)	7	CR (7) PR (2)	14 (2-24)
Mazzaro et al[85]	18	SLVL (1), FL (1), LPL (16)	16-2-2-16	13	IFN + RBV (8)	3	CR (3) PR (2)	18 (8-32)
					PEG-IFN + RBV (10)	6	CR (6) PR (2)
Paulli et al[98]	2	MZL/MALT (2)	Cutaneous	2	PEG-IFN + RBV	2	CR (1) PR (1)	NotR
Pellicelli et al[88]	9	SMZL (3) MZL (4) FL (2)	NR	4	PEG-IFN + RBV (9)	7	CR (5) PR (2)	12

MZL: Marginal zone lymphoma; SMZL: Splenic marginal zone lymphoma; SLVL: Splenic lymphoma with villous lymphocytes; FL: Follicular lymphoma; LPL: Lymphoplasmacytic lymphoma; BM: Bone marrow; S: Spleen; LN: Lymph nodes; PB: Peripheral blood; IFN: Alfa2a/Alfa2b interferon 3 times a week; RBV: Ribavirin; PEG-IFN: Pegylated alfa2a/alfa2b interferon; CR: Complete remission; PR: Partial remission; NR: No response; SVR: Sustained virological response; NotR: Not reported.